AD blood‐based biomarker–cognition associations were domain‐differentiated and context‐dependent: Concurrent associations did not reliably indicate associations with cognition 6 years later, and only p‐tau181 showed formal evidence of relative memory‐versus‐executive selectivity.
Abstract
Abstract INTRODUCTION Whether Alzheimer's disease (AD) blood biomarker–cognition associations differ across cognitive domains, analytic context, and biomarker modeling strategy in population‐based cohorts is unclear.
Methods
In 1170 older adults from the Health and Retirement Study Harmonized Cognitive Assessment Protocol (HRS‐HCAP), we examined cross‐sectional (2016) and prospective (2016 to 2022) associations of blood phosphorylated tau at threonine 181 (p‐tau181), glial fibrillary acidic protein (GFAP), neurofilament light (NfL), and amyloid beta 42/40 ratio (Aβ42/40) with memory, executive function, language, visuospatial ability, and global cognition using individual‐biomarker, principal component analysis‐derived composite, and multi‐biomarker panel models.
Results
Cross‐sectionally, NfL and GFAP showed the broadest associations with cognitive performance. In simultaneous models of baseline‐adjusted follow‐up cognition, p‐tau181 was associated with lower memory (β = −0.080, q < 0.001) and global cognition (β = −0.066, q < 0.001), while GFAP was associated with lower executive function (β = −0.047, q = 0.007), memory (β = −0.047, q = 0.032), and global cognition (β = −0.066, q = 0.002). NfL and Aβ42/40 were not independently associated after mutual adjustment. P‐tau181 also showed relative domain selectivity between memory and executive function. Relative model support differed by cognitive domain and analytic context.
Discussion
AD blood‐based biomarker–cognition associations were domain‐differentiated and context‐dependent: Concurrent associations did not reliably indicate associations with cognition 6 years later, and only p‐tau181 showed formal evidence of relative memory‐versus‐executive selectivity. Exploratory pairwise comparisons highlighted p‐tau181 + GFAP for follow‐up memory and global cognition, warranting independent evaluation.
Abstract INTRODUCTION This study aimed to assess intra‐individual cognitive variability (IICV) in relation to Alzheimer's disease (AD) biomarkers. METHODS The National Alzheimer's Coordinating Center sample (n = 879), aged 50+ with a complete neuropsychological evaluation and AD biomarker data available (64% cognitivel...
S. S. Lin, Alicia L. Milam, Andrew Kiselica et al.· Alzheimer's & Dementia· 0 citations
Alzheimer's disease (AD) is increasingly recognized as a multicellular disorder involving neurovascular unit dysfunction. Investigating glial and vascular biomarkers together may provide a more integrated view of AD biology. This study characterized baseline distributions, interrelationships, and longitudinal trajector...
Higher plasma YKL‐40 was associated with greater white matter hyperintensity (WMH), whereas higher plasma GFAP was related to increased 18F‐florbetapir (FBP) standardized uptake value ratio (SUVR) and higher plasma p‐tau217 was associated with reduced MTL cortical thickness and hippocampal volume.
Batool Rizvi, Jenna N. Adams, Alison R. Bamford et al.· Alzheimer's & Dementia· 1 citation
BAG is a reliable non-invasive marker of structural brain health sensitive to AD pathology and to modifiable AD risk and supports its relevance for early risk stratification and prevention-oriented research.
E. Kuhn, G. Antopoulos, L. Kleineidam et al.· medRxiv· 0 citations
Abstract INTRODUCTION Cross‐sectional studies link Alzheimer's disease (AD) pathogenesis to mild behavioral impairment (MBI), but longitudinal evidence remains limited. We examined whether plasma phosphorylated tau (p‐tau)181 predicts progression of an MBI‐proxy over 2 years in pre‐frail and frail older adults with mil...
F. Bellelli, E. González, Alberta Peluso et al.· Alzheimer's & Dementia· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.